New Delhi: India’s indigenous COVID-19 vaccine, Covaxin, was found to have an efficacy rate of 77.8 per cent against symptomatic COVID-19, according to a long-awaited analysis published in The Lancet.
Covaxin is developed by the India government’s medical research agency and Hyderabad-based Bharat Biotech International Ltd.
Covaxin, which uses traditional, inactivated-virus technology, “induces a robust antibody response” two weeks after two doses are given, the medical journal was quoted as saying in a statement by Bloomberg.
The trial involving 24,419 participants aged 18-97 years between November 2020 and May 2021 in India found no vaccine-related deaths or adverse events, the journal said.
Funded by Bharat Biotech and the Indian Council of Medical Research (ICMR) and partially authored by officials at both bodies, the interim study was in line with the company’s earlier efficacy and safety announcements.
ALSO READ: UK Approves Covaxin; No Quarantine For Fully Vaccinated Travellers
Mumbai: Television actress Hina Khan, who is battling breast cancer, recently met host Salman Khan…
Mumbai: Following reports of his alleged link-up with bassist Mohini Dey, renowned music composer AR…
Mumbai: The love story of actors Tamannaah Bhatia and Vijay Varma has not been clandestine.…
Puri: Shree Jagannath Temple Administration (SJTA) has received the report of the Ratna Bhandar’s GPR-GPS…
With his debut novel ‘The Other Side of the Rainbow’ published recently, Niranjan Nayak, an…
Bhubaneswar: Odisha outplayed Chhattisgarh 4-1 on Saturday to seal a berth in the final round…
Mumbai: The Telangana government’s notice barring him from singing songs promoting alcohol and drugs at…
Bhubaneswar: Prime Minister Narendra Modi will participate in the ‘Odisha Parba 2024’ programme on Sunday…